Circulation Journal
Online ISSN : 1347-4820
Print ISSN : 1346-9843
ISSN-L : 1346-9843
Cardiovascular Intervention
Two-Year Clinical Outcome After Abciximab-Coated Stent Implantation in Patients With Coronary Artery Disease
Sung Soo KimYoung Joon HongMyung Ho JeongWeon KimHyun-Kuk KimJum Suk KoMin Goo LeeDoo Sun SimKeun Ho ParkNam Sik YoonHyun Ju YoonKye Hun KimHyung Wook ParkJu Han KimYoungkeun AhnJeong Gwan ChoJong Chun ParkSun-Jung SongDong Lyun ChoJung Chaee Kang
Author information

2010 Volume 74 Issue 3 Pages 442-448


Background: Despite abciximab-coated stents having an inhibitory effect on coronary artery restenosis, the medium-term clinical outcome is unknown. Methods and Results: This prospective, randomized study compared the effects of the abciximab-coated stent, which was implanted in 95 patients, with those of control bare metal stents (BMS) implanted in 93 patients for de novo coronary lesions. Stent implantation was performed without any complications associated with the procedure. The 6-month intravascular ultrasound analysis showed that the area of neointimal hyperplasia was significantly smaller in the abciximab-coated stent group compared with the control stent group (+2.0±1.6 mm2 vs +3.4±1.7 mm2, P=0.001). However, at 2-year clinical follow up, there were no statistically significant differences in the incidences of total major adverse cardiac events (16% vs 24%, P=0.19) and cardiac death (0% vs 1.1%, P=0.3), target vessel revascularization (16% vs 21%, P=0.4) or non-fatal myocardial infarction (0% vs 2.3%, P=0.16) in the abciximab-coated stent group compared with the control stent group. Conclusions: Although abciximab-coated stents are safe and inhibit neointimal hyperplasia, they have no superiority over BMS in 2-year clinical outcome. (Circ J 2010; 74: 442 - 448)

Content from these authors
Previous article Next article